LA
CMLFU

Lee Ainslie’s CM Life Sciences, Inc. Unit CMLFU Stock Holding History

Lee Ainslie’s Portfolio CMLFU Stock Details CMLFU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-39,302
Closed -$456K – 914
2020
Q4 		$456K Sell
39,302
-487,668
-93% -$5.25M 0.01% 378
2020
Q3 		$5.52M Buy
+526,970
New +$5.54M 0.1% 60

Other funds holding CMLFU

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BCP
Berylson Capital Partners Boston, Massachusetts $41.2M AUM 0.19% 1-Year Est. Return
GS
Gagnon Securities New York $519M AUM 44.91% 1-Year Est. Return
IM
Islet Management New York $49.1M AUM 17.59% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $3.04B AUM 26.78% 1-Year Est. Return
GA
Gagnon Advisors New York $157M AUM 36.77% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return
ACM
Arrow Capital Management New York $181M AUM
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
JG
Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return

Lee Ainslie's CMLFU Position: Q1 2021 in Review

Lee Ainslie sold out of CM Life Sciences, Inc. Unit (CMLFU) in Q1 2021, closing a stake of 39,302 shares — an estimated $456K sold.

Lee Ainslie first reported a position in CMLFU in Q3 2020 and held it in 2 quarters. The position peaked at $5.52M in Q3 2020. 21 funds tracked by Wall St. Rank hold CMLFU as of Q1 2021.

  • Lee Ainslie reported no remaining CM Life Sciences, Inc. Unit position as of Q1 2021 after selling out during the quarter.
  • Lee Ainslie sold 39,302 CM Life Sciences, Inc. Unit shares in Q1 2021, an estimated $456K.
  • Lee Ainslie first reported a position in CM Life Sciences, Inc. Unit in Q3 2020 and held it in 2 quarters.
  • Lee Ainslie's CM Life Sciences, Inc. Unit position peaked at $5.52M in Q3 2020.
  • 21 funds tracked by Wall St. Rank held CM Life Sciences, Inc. Unit as of Q1 2021.

Based on Maverick Capital's 13F filing for Q1 2021, filed 17 May 2021.